in "The Lancet" Monday. From December 2020 to August 2021, researchers studied and analyzed more than 3.4 million health records from people 12 years and older at Kaiser Permanente Southern California who were fully vaccinated with the Pfizer-BioNTech vaccine. RELATED: Pfizer vaccine 88% effective against delta variant, study finds"Our results reiterate in a real-world US setting that vaccination with BNT162b2 [Pfizer-BioNTech vaccine] remains an essential tool for preventing COVID-19, especially COVID-19-associated hospital admissions, caused by all current variants of concern," the study’s authors said.
Researchers said they conducted the study to see how the Pfizer-BioNTech vaccine is holding up against the multiple circulating COVID-19.